Discontinued — last reported Q4 '25
D&A
McKesson D&A increased by 4.8% to $65.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 12.1%, from $58.00M to $65.00M. Over 3 years (FY 2022 to FY 2025), D&A shows a downward trend with a -4.6% CAGR.
Analysis
How to read this metric
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
Detailed definition
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Peer comparison
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
depreciation_and_amortization_cfHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $80.00M | $68.00M | $67.00M | $64.00M | $61.00M | $63.00M | $61.00M | $63.00M | $64.00M | $65.00M | $62.00M | $62.00M | $63.00M | $61.00M | $58.00M | $60.00M | $62.00M | $62.00M | $65.00M |
| QoQ Change | — | -15.0% | -1.5% | -4.5% | -4.7% | +3.3% | -3.2% | +3.3% | +1.6% | +1.6% | -4.6% | +0.0% | +1.6% | -3.2% | -4.9% | +3.4% | +3.3% | +0.0% | +4.8% |
| YoY Change | — | — | — | — | -23.8% | -7.4% | -9.0% | -1.6% | +4.9% | +3.2% | +1.6% | -1.6% | -1.6% | -6.2% | -6.5% | -3.2% | -1.6% | +1.6% | +12.1% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Medical-Surgical Solutions | $23.00M | $22.00M | $23.00M | $25.00M | $22.00M | $23.00M | $26.00M | $25.00M |
| Prescription Technology Solutions | $21.00M | $22.00M | $22.00M | — | $21.00M | $20.00M | $21.00M | $20.00M |
| International | $30.00M | — | — | — | $14.00M | — | — | — |
| North American Pharmaceutical | — | — | — | — | — | $32.00M | $34.00M | — |
| Oncology & Multispecialty | — | — | — | — | — | $71.00M | $63.00M | — |
| U.S. Pharmaceutical | $60.00M | — | — | — | $63.00M | — | — | — |
| Total | $63.00M | $61.00M | $58.00M | $60.00M | $62.00M | $62.00M | $65.00M | — |
International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is McKesson's d&a?
- McKesson (MCK) reported d&a of $65.00M in Q4 2025.
- How has McKesson's d&a changed year-over-year?
- McKesson's d&a increased by 12.1% year-over-year, from $58.00M to $65.00M.
- What is the long-term trend for McKesson's d&a?
- Over 3 years (2022 to 2025), McKesson's d&a has grown at a -4.6% compound annual growth rate (CAGR), from $279.00M to $242.00M.
- What does d&a mean?
- The accounting process of spreading the cost of physical and intangible assets over time.